DexCom (DXCM) - FREE Research Report

Gregg Terrance H who is Ceo at DexCom sold 9,000 shares at $28.33 on Nov. 5, 2013. Following this transaction, the Ceo owned 741,889 shares meaning that the stake was reduced by 1.2% with the 9,000 share transaction.

The shares most recently traded at $27.62, down $0.71, or 2.57% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 24-Week # shares sold: 17,361

The average volume for DexCom has been 538,200 shares per day over the past 30 days. DexCom has a market cap of $2.0 billion and is part of the health care sector and health services industry. Shares are up 109.27% year to date as of the close of trading on Tuesday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 8 analysts that rate DexCom a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Cloud Software Is Booming -- Just Ask Workday and Salesforce

Cloud Software Is Booming -- Just Ask Workday and Salesforce

ServiceNow Is NOW Poised for a Breakout

Cramer: How Picking Stocks Is Like Fantasy Football